Sunday, November 8, 2026

USD/CNH Is 2% Down In The Last 21 Sessions

ViaNews Editorial Team

November 30, 2023

USD/CNH Is 2% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.33% for the last 21 sessions. At 15:14 EST on Thursday, 30 November, USD/CNH (USDCNH) is $7.15.

USD/CNH's yearly highs and lows, it's 0.386% up from its 52-week low and 0.048% down from its 52-week high.

News about

  • Eur/usd settling back after testing 15-week high above 1.1000. According to FXStreet on Tuesday, 28 November, "The EUR/USD is easing back into the 1.0980 neighborhood after tipping into a 15-weekhigh just above 1.1000, bolstered by a broad-market uptick in risk appetite, pushing the US Dollar (USD) down across the board and into the red against all other major currencies on Tuesday.", "The Relative Strength Index (RSI) is flashing warning signs that the EUR/USD may have gone too far, too quickly with the signal line testing into the overbought boundary line, and the pair could see an extended pullback if bears are able to capitalize on any profit-taking."
  • Eur/usd to rise towards 1.10 on a break past 1.0960 resistance – socgen. According to FXStreet on Tuesday, 28 November, "Month-end equity portfolio rebalancing flows could renew EUR/USD buying interest this week and guide the pair back above 1.0960 resistance which stands in the way of a rise to 1.10.", "The combination of China stimulus (housing/ foreign orders) and lower oil prices are supportive for higher EUR/USD so long as the bear steepening in US yields does not reignite."
  • According to FXStreet on Tuesday, 28 November, "A return to 0.9713 (200-DMA) still appears ambitious with a push in EUR/USD above 1.10."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com